CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012

[January 11, 2013]

Research and Markets: FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/hct3j6/flublok_seasonal) has announced the addition of GlobalData's new report "FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis" to their offering.

FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection.

Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of th market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

FluBlok is being developed by the Protein Sciences Corporation (PSC), headquartered in Meriden, Connecticut in the US. FluBlok is the leading vaccine candidate in PSC's vaccine portfolio that also focuses on pandemic influenza, SARS and flu vaccine adjuvants. The trivalent vaccine consists of recombinant hemagglutinin protein, from H1, H3 and B strains, that are propagated in a baculovirus expression vector system in insect cells (FDA Briefing document). The vaccine is a first-in-class product that is the first vaccine to use an insect cell-based manufacturing system in the US.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Appendix

For more information visit http://www.researchandmarkets.com/research/hct3j6/flublok_seasonal

Source (News - Alert): GlobalData


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter